Inter-individual variability in drug response is a major clinical problem.
Adverse drug reactions (ADRs) are common, are responsible for a number of debilitating side effects following drug therapy and are a significant cause of death.
It is now clear that much of the observed variability in drug response has a genetic basis, arising as a result of genetically-determined differences in drug absorption, disposition, metabolism or excretion.
The best characterised pharmacogenetic polymorphisms are those within the phase I cytochrome P450 family of drug metabolising enzymes.
One of these enzymes, CYP2D6 (debrisoquine hydroxlyase), metabolises one-quarter of all prescribed drugs and is inactive in 6% of the Caucasian population.
Individuals at risk of developing ADRs as a result of genetically-determined variation in genes such as CYP2D6 can now be identified using DNA-based tests.
A detailed knowledge of the genetic basis of individual drug response is potentially of major clinical and economic importance and could provide the basis for a rational approach to drug prescription.
This would have significant benefits for human health.
Mots-clés Pascal : Pharmacogénétique, Effet secondaire, Toxicité, Chimiothérapie, Prescription médicale, Métabolisme, Médicament, Exploration, Homme
Mots-clés Pascal anglais : Pharmacogenetics, Secondary effect, Toxicity, Chemotherapy, Medical prescription, Metabolism, Drug, Exploration, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0470038
Code Inist : 002A31C02A2. Création : 22/03/2000.